A Phase 2a, Randomized, Double-blind, Placebo (Vehicle)-Controlled, Dose Finding Trial to Assess the Safety, Tolerability and Efficacy of NRD135S.E1 in Patients With Neuropathic Pain Associated With Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2016
At a glance
- Drugs NRD135S E1 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Novaremed
- 25 Jul 2016 Status changed from recruiting to completed.
- 20 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 29 Jan 2015 New trial record